Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AC Immune stock logo
ACIU
AC Immune
$2.06
+2.0%
$1.82
$1.43
$4.26
$207.85M1.62144,985 shs113,290 shs
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
$14.70
+0.1%
$14.64
$6.41
$14.77
$940.21M0.84757,360 shs2.39 million shs
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$2.49
+0.4%
$2.06
$0.40
$3.10
$201.55M2.052.20 million shs755,783 shs
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$91.18
+1.2%
$81.23
$15.80
$99.01
$7.42B0.241.26 million shs436,269 shs
XBiotech Inc. stock logo
XBIT
XBiotech
$3.17
-1.7%
$2.87
$2.50
$8.32
$96.95M0.9869,208 shs28,527 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AC Immune stock logo
ACIU
AC Immune
0.00%+2.49%+19.08%+24.10%-45.93%
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
0.00%0.00%0.00%0.00%0.00%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
0.00%+10.67%+3.75%+446.53%+91.54%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
0.00%-2.81%+6.59%+69.17%+480.39%
XBiotech Inc. stock logo
XBIT
XBiotech
0.00%+13.04%+10.66%+10.28%-45.34%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AC Immune stock logo
ACIU
AC Immune
2.4456 of 5 stars
3.53.00.00.02.00.80.6
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
4.0575 of 5 stars
3.51.00.04.71.21.71.3
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
2.7753 of 5 stars
3.51.00.00.03.52.50.6
XBiotech Inc. stock logo
XBIT
XBiotech
0.4697 of 5 stars
0.00.00.00.02.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AC Immune stock logo
ACIU
AC Immune
3.00
Buy$12.00482.52% Upside
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
0.00
N/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.00
Buy$5.33114.19% Upside
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
3.00
Buy$107.3617.75% Upside
XBiotech Inc. stock logo
XBIT
XBiotech
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CTMX, XBIT, AMYT, ACIU, and VRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$170.00
6/23/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$76.00 ➝ $160.00
6/20/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$107.00 ➝ $138.00
6/18/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$92.00 ➝ $116.00
6/11/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $100.00
6/11/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$95.00 ➝ $110.00
6/2/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$85.00 ➝ $90.00
5/15/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$2.50 ➝ $5.00
5/15/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$5.00 ➝ $5.00
5/12/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$5.00 ➝ $6.00
5/1/2025
AC Immune stock logo
ACIU
AC Immune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $12.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AC Immune stock logo
ACIU
AC Immune
$28.30M7.31N/AN/A$1.29 per share1.60
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
$222.54M4.22$0.98 per share14.98$5.58 per share2.63
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$147.56M1.36$0.36 per share6.91($0.01) per share-249.00
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$118.54M62.37N/AN/A$2.56 per share35.62
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/A$5.98 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AC Immune stock logo
ACIU
AC Immune
-$57.83M-$0.58N/AN/AN/A-177.79%-44.60%-22.25%8/5/2025 (Estimated)
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
$1M-$0.06N/A735.00N/A-8.19%1.70%0.75%N/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$31.87M$0.485.19N/AN/A28.22%-553.71%32.21%8/14/2025 (Estimated)
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$173.42M-$2.00N/A3,039.33N/AN/A-69.65%-28.00%8/6/2025 (Estimated)
XBiotech Inc. stock logo
XBIT
XBiotech
-$38.53M-$1.29N/AN/AN/A-21.14%-19.55%8/11/2025 (Estimated)

Latest CTMX, XBIT, AMYT, ACIU, and VRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
XBiotech Inc. stock logo
XBIT
XBiotech
N/A-$0.36N/A-$0.36N/AN/A
5/12/2025Q1 2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$0.18$0.27+$0.09$0.27$35.42 million$50.92 million
4/30/2025Q1 2025
AC Immune stock logo
ACIU
AC Immune
-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 million
4/29/2025Q1 2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AC Immune stock logo
ACIU
AC Immune
N/AN/AN/AN/AN/A
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
N/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
N/AN/AN/AN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AC Immune stock logo
ACIU
AC Immune
N/A
1.53
1.53
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
0.64
1.57
0.94
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
1.73
1.73
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
1.07
8.86
8.73
XBiotech Inc. stock logo
XBIT
XBiotech
N/A
29.15
29.15

Institutional Ownership

CompanyInstitutional Ownership
AC Immune stock logo
ACIU
AC Immune
51.36%
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
71.31%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
67.77%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
85.88%
XBiotech Inc. stock logo
XBIT
XBiotech
55.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
AC Immune stock logo
ACIU
AC Immune
140100.41 million95.79 millionOptionable
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
2,02063.96 million60.34 millionNot Optionable
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
17080.62 million75.30 millionOptionable
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
3081.08 million81.05 millionOptionable
XBiotech Inc. stock logo
XBIT
XBiotech
10030.49 million20.40 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AC Immune stock logo

AC Immune NASDAQ:ACIU

$2.06 +0.04 (+1.98%)
Closing price 07/3/2025 02:31 PM Eastern
Extended Trading
$2.06 0.00 (0.00%)
As of 07/3/2025 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Amryt Pharma stock logo

Amryt Pharma NASDAQ:AMYT

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

CytomX Therapeutics stock logo

CytomX Therapeutics NASDAQ:CTMX

$2.49 +0.01 (+0.40%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$2.49 0.00 (0.00%)
As of 07/3/2025 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Verona Pharma PLC American Depositary Share stock logo

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$91.18 +1.10 (+1.22%)
Closing price 07/3/2025 03:13 PM Eastern
Extended Trading
$91.42 +0.24 (+0.26%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

XBiotech stock logo

XBiotech NASDAQ:XBIT

$3.16 -0.06 (-1.71%)
As of 07/3/2025 02:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.